Company news
Sinovac Biotech, Ltd. (NASDAQ:SVA) news
Sinovac Biotech, Ltd. news releases on 6ix. Latest, Aug 29, 2023: Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer
Press releases — page 2
Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer
August 28, 2023
Sinovac Announces Change of Legal Representative of Sinovac Beijing
August 27, 2023
SINOVAC Reports Unaudited First Half of 2023 Financial Results
August 14, 2023
SINOVAC’s CoronaVac® Answers Hong Kong’s Need for Self-Pay COVID-19 Vaccines
May 9, 2023
SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F
April 30, 2023
SINOVAC Reports Unaudited First Half of 2022 Financial Results
December 28, 2022
SINOVAC Varicella Vaccine Prequalified by WHO
November 2, 2022
SINOVAC to Showcase Products at CPHI Frankfurt
October 27, 2022
SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile
September 5, 2022
SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong
August 2, 2022
SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile
July 18, 2022
SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil
July 13, 2022
SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa
June 24, 2022
SINOVAC Polio Vaccine Prequalified by WHO
June 7, 2022
SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act
May 5, 2022
SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
April 28, 2022
SINOVAC Reports Unaudited First Half of 2021 Financial Results
December 29, 2021
Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment
December 8, 2021
SINOVAC Beijing Settled Litigation of Its Business License and Seals
December 2, 2021
Preliminary Results Show SINOVAC’s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population
November 8, 2021
New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant
September 8, 2021
SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents
September 7, 2021
SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations
August 9, 2021
SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy
July 18, 2021
SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX
July 11, 2021
The Lancet Infectious Diseases Published Data from Sinovac’s Phase I/II Study, World’s First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old
June 29, 2021
World Health Organization Authorizes SINOVAC’s CoronaVac® for Emergency Use
June 1, 2021
Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F
April 21, 2021
Sinovac Announced Buildup of Two Billion Annual Capacity of Its COVID-19 Vaccine
March 31, 2021
Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine
February 7, 2021
Sinovac Announces Phase III Results of Its COVID-19 Vaccine
February 4, 2021
Sinovac Files for Conditional Market Authorization of COVID-19 Vaccine in China
February 2, 2021
Sinovac Announces Product License for 23-Valent Pneumococcal Polysaccharide Vaccine
December 8, 2020
Sinovac Reports Unaudited Third Quarter 2020 Financial Results
December 6, 2020
Sinovac Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development
December 5, 2020
Beijing Fourth Intermediate People’s Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan
September 27, 2020
Sinovac’s Coronavac™, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children
September 22, 2020
Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey
September 21, 2020
Sinovac Reports Preliminary Phase I/II Results of COVID-19 Vaccine in Elderly Volunteers
September 8, 2020
Sinovac Reports Unaudited Second Quarter 2020 Financial Results
August 27, 2020
Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation
August 24, 2020
Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial
July 5, 2020
Sinovac Reports Unaudited First Quarter 2020 Financial Results
June 29, 2020
Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine
June 23, 2020
Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19
June 12, 2020
Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III
June 10, 2020
Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development
May 21, 2020
Sinovac Comments on SEC Findings Against Jiaqiang "Chiang" Li and 1Globe Capital
May 17, 2020
Sinovac Announces First Animal Study Results of Vaccine Against COVID-19 Published in SCIENCE
May 5, 2020
Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F
April 29, 2020